Value of cytosine arabinoside (NSC-63878) plus 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) therapy in advanced murine L1210 leukemia and enhancement of the combination with sequential doses of methotrexate (NSC-740) or 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
D000577:Amides / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001201:Ascites; D003561:Cytarabine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D007093:Imidazoles / Q000627:therapeutic use*; D007939:Leukemia L1210 / Q000188:drug therapy*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use*; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D013997:Time Factors; D014226:Triazenes / Q000627:therapeutic use*
D000577:Amides; D000970:Antineoplastic Agents; D007093:Imidazoles; D009607:Nitrosourea Compounds; D014226:Triazenes; D003561:Cytarabine; D008727:Methotrexate